<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) are a biologically and clinically <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> entity </plain></SENT>
<SENT sid="1" pm="."><plain>Although some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> represent transformation of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FL), the proportion that is of follicular center cell (FCC) origin remains uncertain </plain></SENT>
<SENT sid="2" pm="."><plain>Immunophenotypic and genotypic markers used to suggest a FCC origin for a <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (bcl-6 and CD10 expression, lack of CD138 expression, bcl-2 rearrangements [R]) or to subdivide <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (bcl-2 expression, bcl-6 R) were therefore investigated in 22 FL and 44 DLBCL using paraffin section immunostains and Southern blot/polymerase chain reaction analysis </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> FL tested were bcl-6+ (19) and CD138- (22) with 16/19 also bcl-2 and CD10+ (classic phenotype), one bcl2+, CD10- (grade III) and two bcl2-, CD10+ (grade II or III) </plain></SENT>
<SENT sid="4" pm="."><plain>Bcl-2R was identified in 4/5 FL-GrI, 3/6 FL-GrII, and 1/3 FL-GrIII </plain></SENT>
<SENT sid="5" pm="."><plain>Bcl-6R was found in 0/5, 2/4, and 0/3 FL, respectively </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but 3/41 DLBCL were bcl-6+ with 17/37 also bcl-2+ and CD10+ </plain></SENT>
<SENT sid="7" pm="."><plain>Three of these cases were also CD138+ </plain></SENT>
<SENT sid="8" pm="."><plain>Twelve bcl-6+ cases were bcl-2+, CD10-, six bcl-2-, CD10+, and two bcl-2-, CD10- </plain></SENT>
<SENT sid="9" pm="."><plain>The three bcl-6- cases were bcl-2+, CD138- and two were CD10+ </plain></SENT>
<SENT sid="10" pm="."><plain>Bcl-2R was identified in 5/27 DLBCL with 4/5 bcl-2+, 3/4 tested CD10+ and 4/4 bcl-6+ </plain></SENT>
<SENT sid="11" pm="."><plain>Bcl-6R was identified in 7/26 including three with a classic FL phenotype </plain></SENT>
<SENT sid="12" pm="."><plain>The vast majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> in this study have an immunophenotype that supports a FCC origin </plain></SENT>
<SENT sid="13" pm="."><plain>Although the proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> that co-expressed bcl-6, CD10 and bcl-2 was lower than for the FL, absence of bcl-2 or CD10 may be associated with higher grade FL It is also possible that bcl-6 expression is not completely specific for a FCC origin </plain></SENT>
<SENT sid="14" pm="."><plain>Only a minority of cases suggested postfollicular differentiation </plain></SENT>
<SENT sid="15" pm="."><plain>Only a minority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> show bcl-2R, suggesting that many have a different molecular pathogenesis than most low-grade FL </plain></SENT>
<SENT sid="16" pm="."><plain>Bcl-6R did not exclude a FCC origin </plain></SENT>
</text></document>